Q: Case managers across the country have faced challenging circumstances for the past six months, and the novel coronavirus (COVID-19) pandemic is hitting a second wave. How can case managers best cope with the added stress and pressures of the job while caring for their patients during these unprecedented times?
Q: What place of service codes and modifiers should be reported on physician claims for wound care services performed via telehealth during the COVID-19 public health emergency?
Q: What are the essential steps when conducting a risk analysis? Are there any sample tools out there to provide guidance on best practices for risk analyses? How often should organizations be conducting these tests?
Q: For the purposes of determining a Medicare overpayment, should claims that we are uncertain whether they were appropriate be included? Is this defined under the False Claims Act (FCA)?
Q: CMS created a new MS-DRG for chimeric antigen receptor T-cell (CAR-T) therapies in the fiscal year (FY) 2021 IPPS final rule. Which ICD-10-PCS codes group to this new MS-DRG and does it qualify for an additional new technology add-on payment?
Q: Workers will likely remain remote for the foreseeable future, but as coffee shops and restaurants begin to reopen, it’s possible that employees may be accessing protected health information (PH) in these locations. While it is best practice to avoid doing this altogether, what should employees do to avoid exposing PHI in this scenario?
Q: CMS recently updated its Care Compare tool, a resource that can provide valuable insight for any patient. How can case managers ensure that their patents can access and best utilize this tool?
